Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer.

Hongxue Meng,Jingshu Geng,Dawei Sun,Geng Tian,Yingmin Han,Yuebin Liang,Shidong Xu,Dawei Yuan,Qingqing Lu,Xuejie Guo,Jidong Lang,Yanxin An,Yanxiang Zhang

doi:10.3389/fgene.2019.01008

Abstract

Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in Non-small-cell lung cancer (NSCLC) Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there were differences between East Asian and non-Asian populations. Further, four promising candidates for druggable mutations of epidermal growth factor receptor (EGFR) were revealed that open up avenues to develop and design personal therapeutic approaches for patients harboring mutations. These results will help to develop personalized therapy targeting NSCLC.

Highlights

Lung cancer is the most frequent cause the mortality compared to other cancer types
Our results were comparable with that detected in previous studies in Chinese lung adenocarcinoma (Gou and Wu, 2014), while the difference is mainly manifested in the different detection frequencies of several fusion genes
Similar to Western population, the two most ubiquitous mutations were those in epidermal growth factor receptor (EGFR) and Kirsten Rat Sarcoma Viral Proto-Oncogene (KRAS) in the case of lung adenocarcinoma samples

Summary

Introduction

Lung cancer is the most frequent cause the mortality compared to other cancer types. Treatment strategies for NSCLC have been revolutionized since the identification of epidermal growth factor receptor (EGFR) activating mutations which predict response to EGFR tyrosine kinase inhibitors (TKIs) in 2004 (Lynch et al, 2004; Paez et al, 2004). Examples of such drugs are erlotinib and gefitinib that have been instrumental in patients in terms of the response and survival without a relapse (Mitsudomi et al, 2010; Rosell et al, 2012). With very little data in this regard from mainland China, a study that

Methods

Results

Conclusion